Selected A-share Announcements | Over 1 Billion US Dollars! Meve Biopharmaceuticals (688062.SH) Innovative Cardiovascular Drug Goes Overseas.

Today's Focus 1. Ping An Insurance: The 2025 Long-Term Service Plan has completed the stock purchase in the secondary market, acquiring a total of 74.615 million H shares of the company at an average price of approximately 51.87 yuan per share. Ping An Insurance announced that the company's 2025 Long-Term Service Plan has completed the stock purchase in the secondary market, acquiring a total of 74.615 million H shares of the company, accounting for 0.412% of the total share capital of the company. The total transaction amount was 3.875 billion yuan, with an average transaction price of approximately 51.87 yuan per share. A total of 83,024 core talents voluntarily participated in the plan. Directors, supervisors, and senior management's shareholding proportion in the plan is 2.52%, while other employees' shareholding proportion is 97.48%. Participants in the Long-Term Service Plan can apply for the ownership of plan rights when they retire from the company. 2. Maiwei Biosciences: Signed an exclusive licensing agreement with Kalexo, with a maximum of $1 billion in upfront and milestone payments. Maiwei Biosciences announced that the company has signed an exclusive licensing agreement and a preferred stock purchase agreement with Kalexo Bio, Inc. for the 2MW7141 project. Under the licensing agreement, Maiwei Biosciences grants Kalexo the exclusive rights to develop, manufacture, commercialize, and otherwise develop licensed products globally. In terms of the transaction amount, Maiwei Biosciences will receive a maximum of $1 billion in upfront and milestone payments from Kalexo, as well as a low single-digit royalty fee, including a one-time, non-refundable initial payment and a near-term payment of $12 million in cash. As part of the consideration, Maiwei Biosciences will also receive a double-digit A-round preferred stock from Kalexo under agreed conditions. The transaction is expected to have a positive impact on the company's future performance and help enhance its profitability. 2MW7141 is a dual-target small nucleic acid drug developed by the company in the preclinical stage, primarily targeting lipid regulation in individuals with lipid abnormalities and the prevention of high-risk cardiovascular events. 3. Hangzhou Anysoft Information Technology: Won the bid for a 170 million yuan artificial intelligence computing power technology service project. Hangzhou Anysoft Information Technology announced that the company has become the winning candidate for Zhejiang Posts and Telecommunications Engineering Construction Co., Ltd.'s artificial intelligence computing power technology service project, with a bid amount of approximately 169.92 million yuan including tax. The project is still in the winning candidate publicity period, and there is uncertainty regarding whether the bid notification letter has been received and the final bid amount. Note: According to incomplete statistics from Cailian... 4. Ningbo TIP Rubber Technology: Uncertainty in the change of control of the company, stock will resume trading on September 18. Ningbo TIP Rubber Technology announced that the company's stock will resume trading from September 18, 2025. The company's stock had consecutive limit-up trading for 11 trading days from August 22 to September 10, with a significant deviation in the short-term rise compared to the Shanghai Composite Index and the auto parts industry index during the same period. The company did not find any need for correction or supplementation to the previously disclosed information, nor did it find any recent public media reports of significant undisclosed information that may have had a significant impact on the company's stock trading price. There is uncertainty in the change of control of the company, and the approval process and timing of approval are still uncertain. The company's price-to-earnings ratio and price-to-book ratio are significantly higher than the industry average, posing a risk of rapid decline in the future. 5. Guangzhou Haozhi Industrial: Director Xiaoyonglin plans to reduce his shareholding by up to 290,000 shares. Guangzhou Haozhi Industrial announced that the company's director, Xiaoyonglin, plans to reduce his shareholding by up to 290,000 shares of the company within three months after 15 trading days from the disclosure of the announcement through centralized bidding or block trading. This represents 0.09% of the total share capital of the company. The reason for the reduction is personal fund arrangement, and the sources of the shares to be reduced include shares granted under the company's 2016 restricted stock incentive plan, shares obtained by capital reserves to increase share capital, and shares acquired through block trading. The reduction price will be determined based on the market price. Xiaoyonglin has committed not to transfer more than 25% of the total shares held during his tenure each year, and not to transfer any shares within six months after leaving the company. This reduction plan is in compliance with relevant laws and regulations, will not lead to a change in the company's control, and will not affect the company's governance and ongoing operations. 6. Xingye Leather Technology: Signed a strategic cooperation agreement with Suzhou Nengsi to jointly develop flexible electronic skin. Xingye Leather Technology announced that the company has signed a strategic cooperation agreement with Suzhou Nengsi Electronic Technology Co., Ltd. to jointly develop flexible electronic skin based on natural leather and bio-based materials. Suzhou Nengsi focuses on the research and industrialization of flexible micro-nano sensor technology, with core design capabilities for a variety of ranges of flexible micro-nano mechanical force sensors (pressure, piezoelectric, strain) and arrays, achieving leading levels in the industrialization of flexible micro-nano sensors in strategic emerging industries such as humanoid Siasun Robot & Automation, consumer electronics, healthcare, and IoT. Xingye Leather Technology is responsible for the research and production of natural leather, high-biocycle regenerated leather, and environmentally friendly materials, while Suzhou Nengsi is responsible for sensor technology. The two parties will jointly research the combination of sensor technology with natural leather and bio-based materials to incubate flexible electronic skin products, among other initiatives. 7. Pinming Technology: Planning for a change in control, stock trading suspended. Pinming Technology announced that the company is planning for a significant event that could result in a change in control of the company. To ensure fair disclosure of information, protect investor interests, and avoid abnormal fluctuations in the stock price, the company's stock will be suspended from September 18, 2025. The suspension period is expected to be no more than 2 trading days. During the suspension period, the company will strictly fulfill its disclosure obligations based on the progress of the event. Once the relevant matters are confirmed, the company will promptly release relevant announcements and apply for the resumption of trading of its stock. 8. Chongqing Zhifei Biological Products: The innovative drug CA111 injection has been approved for Phase I clinical trials in overweight or obese adult patients. Chongqing Zhifei Biological Products announced that the company's holding subsidiary, Cheran Biotech, has received a drug clinical trial approval notice from the National Medical Products Administration to conduct Phase I clinical trials of the CA111 injection in overweight or obese adult patients. The injection is a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, with broad market prospects. The CA111 injection is an innovative drug developed by Cheran Biotech and is classified as a Class 1 chemical drug according to the drug registration category. Cheran Biotech holds valid invention patents for the molecular structure and application of CA111, with broad market prospects in the diabetes and weight loss treatment fields. 9. Zhejiang Huahai Pharmaceutical: Subsidiary receives FDA approval to conduct Phase I clinical trials for the HB0043 injection. Zhejiang Huahai Pharmaceutical announced that its subsidiary, Shanghai Huahangzhou Alltest Biotech Pharmaceuticals Co., Ltd., has received approval from the U.S. FDA to conduct Phase I clinical trials for the HB0043 injection in the United States. The drug is a recombinant humanized IgG1 bispecific antibody used to treat pyogenic hidradenitis and other autoimmune diseases. The company has invested approximately 71.11 million yuan in the project. HB0043 is the world's first bispecific drug targeting IL-17A and IL-36R, with the potential to overcome the limitations of existing single-target therapies. 10. Ningbo Tuopu Group: Controlling shareholder and his son terminate the share reduction plan in advance, reducing a total of 3.4936 million shares. Ningbo Tuopu Group announced that the company's controlling shareholder and chairman, Wu Jianshu, and vice chairman, director Wu Haonian, have decided to terminate the share reduction plan in advance. During the implementation of the reduction plan, Wu Jianshu reduced his holdings by 2.9983 million shares through centralized bidding, accounting for approximately 0.1725% of the total share capital of the company, at a price range of 62.81-73.03 yuan per share; Wu Haonian reduced his holdings by 495,300 shares, accounting for approximately 0.0285% of the total share capital of the company, at a price range of 62.49-63.83 yuan per share. The two have reduced a total of 3.4936 million shares, accounting for 0.2010% of the total share capital of the company. The reason for the early termination of the reduction plan is that their financial needs have been met. 11. Jiangsu Hengrui Pharmaceuticals: Injection Rui Kang Qutuzumab for the new indication of treating breast cancer patients approved and included in priority review. Jiangsu Hengrui Pharmaceuticals announced that its subsidiary, Suzhou Shengdiya Biomedicine Co., Ltd., has received an "Acceptance Notice" from the National Medical Products Administration for the listing application of the injection Rui Kang Qutuzumab (SHR-A1811) for the new indication of treating locally advanced or metastatic HER2-positive adult breast cancer patients who have previously received one or more anti-HER2 drugs. The application has been accepted by the National Medical Products Administration and has been included in the priority review process. The drug has already been approved for sale in China and is indicated for the treatment of adult patients with HER2 (ERBB2) activating mutations who have previously received at least one systemic therapy and have unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC). 12. China Resources Sanjiu Medical & Pharmaceutical: Plans to invest up to 10 billion yuan in bank financial products with its own funds. China Resources Sanjiu Medical & Pharmaceutical announced that the company and its subsidiaries plan to invest a total of up to 10 billion yuan in bank financial products with their own funds (excluding Bank of Zhuhai Huarun financial products), with funds available for rolling use and individual product terms not exceeding six months. 13. Anhui Anke Biotechnology: Jointly invested company PA3-17 injection approved for crucial Phase II clinical trial, the world's first autologous CAR-T cell therapy product targeting CD7 to receive clinical trial approval. Anhui Anke Biotechnology announced that its joint venture company Boshengji Medical Technology (Suzhou) Co., Ltd. and Boshengji Anke Cell Technology Co., Ltd. have received the minutes of the Phase II communication meeting for the PA3-17 injection issued by the Drug Evaluation Center of the National Medical Products Administration, allowing the applicant to conduct the crucial Phase II clinical trial for the PA3-17 injection. The PA3-17 injection is the world's first autologous CAR-T cell therapy product targeting CD7, approved for a new drug clinical trial. It is used to treat adult patients with recurrent, refractory CD7-positive hematologic malignancies. 14. Sino-High: Controlling shareholder and actual controller plan to reduce their holdings by no more than 2% of the company's shares. Sino-High announced that the controlling shareholder and actual controller, Qin Cuie, plans to reduce their holdings by a total of no more than 3.4976 million shares within three months after fifteen trading days from the disclosure of the announcement through centralized bidding and block trading, representing approximately 2% of the total share capital of the company. 15. Changchun High-Tech Industry: Subsidiary enters into a cooperation agreement with Denmark's ALK-Abell A/S to develop allergen-specific immunotherapy (AIT) products. Changchun High-Tech Industry announced that the 11th board of directors' 13th meeting approved the proposal on the cooperation between the subsidiary Changchun Jinsai Pharmaceutical Co., Ltd. and Denmark's ALK-Abell A/S in developing and commercializing ALK's house dust mite (HDM) allergen-specific immunotherapy products in mainland China and obtained the exclusive agent rights for three products developed by ALK in mainland China. (C) This article is reproduced from "Tencent Self-selected Stocks", GMTEight Editor: Xu Wenqiang.